A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

NCT03343652 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

DRUG: Nivolumab
DRUG: Bendamustine Hydrochloride

Sponsor

St. Petersburg State Pavlov Medical University